Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases

Fotios Loupakis,Shruti Sharma,Madiha Derouazi,Sabina Murgioni,Paola Biason,Mario Domenico Rizzato,Cosimo Rasola,Derrick Renner,Svetlana Shchegrova,Allyson Koyen Malashevich,Meenakshi Malhotra,Himanshu Sethi,Bernhard Zimmermann,Alexey Aleshin,Solomon Moshkevich,Paul Billings,Jonathon Sedgwick,Marta Schirripa,Giada Munari,Umberto Cillo,Pierluigi Pilati,Angelo Paolo Dei Tos,Vittorina Zagonel,Sara Lonardi,Matteo Fassan

Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases

2021

PURPOSEMore than 50% of patients with stage IV colorectal cancer (metastatic colorectal cancer [mCRC]) relapse postresection. The efficacy of postoperative systemic treatment is limited in this set...

Keywords:

Oncology
Stage IV Colorectal Cancer
Resection
Colorectal cancer
Disease
Internal medicine
Circulating tumor DNA
Medicine
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations